請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38540
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭永銘 | |
dc.contributor.author | Ling Chung | en |
dc.contributor.author | 鍾翎 | zh_TW |
dc.date.accessioned | 2021-06-13T16:36:43Z | - |
dc.date.available | 2012-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-18 | |
dc.identifier.citation | 1. Parkin, A., K.E. Goldstone, and P.J. Robinson, Hepatic perfusion index measured using MRI and scintigraphy. Br J Radiol, 2005. 78(936): p. 1118-.
2. Regimbeau, J.M., et al., Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: Results of a multicenter study. Journal of Surgical Oncology, 2004. 85(1): p. 36-41. 3. Boffetta P, et al., Meta-analysis of studies of occupational exposure to vinyl chloride in relation to cancer mortality. Scandinavian Journal of Work Environment and Health, 2003. 29(3): p. 220-229. 4. Soini Y, et al., An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis, 1996. 17(5): p. 1007-12. 5. Maheshwari, S., et al., Oral contraception and the risk of hepatocellular carcinoma. Journal of hepatology, 2007. 47(4): p. 506-513. 6. Wideroff, L., et al., Cancer Incidence in a Population-Based Cohort of Patients Hospitalized With Diabetes Mellitus in Denmark. Journal of the National Cancer Institute, 1997. 89(18): p. 1360-1365. 7. Regimbeau, J.M., et al., Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transplantation, 2004. 10(S2): p. S69-S73. 8. Hellerbrand, C., et al., HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2003. 1(4): p. 279-284. 9. Tomimaru, Y., et al., Fibrosis in Non-cancerous Tissue is the Unique Prognostic Factor for Primary Hepatocellular Carcinoma Without Hepatitis B or C Viral Infection. World Journal of Surgery, 2006. 30(9): p. 1729-1735. 10. Donato, F., et al., Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women. American Journal of Epidemiology, 2002. 155(4): p. 323-331. 11. Tagger, A., et al., Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol. International Journal of Cancer, 1999. 81(5): p. 695-699. 12. Blum, H.E., Hepatocellular carcinoma: Therapy and prevention. World Journal of Gastroenterol, 2005. 11(47): p. 7391-7400 13. Branda, M. and J.R. Wands, Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology, 2006. 43(5): p. 891-902. 14. Wright, W.E. and J.W. Shay, Telomere positional effects and the regulation of cellular senescence. Trends in Genetics, 1992. 8(6): p. 193-197. 15. Hsu, I.C., Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 1991. 350: p. 427-428. 16. Bressac, B., et al., Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991. 350(6317): p. 429-431. 17. Higashitsuji, H., et al., The Oncoprotein Gankyrin Negatively Regulates Both p53 and RB by Enhancing Proteasomal Degradation. Cell Cycle, 2005. 4(10): p. 1335-1337. 18. Ori, A., et al., p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J, 1998. 17(2): p. 544-553. 19. Doitsh, G. and Y. Shaul, HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX. Oncogene, 1999. 18(52): p. 7506-7513. 20. Dynlacht, B., et al., Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes and Development, 1994 8(15): p. 1772-86. 21. Malumbres, M. and M. Barbacid, Milestones in cell division : To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer, 2001. 1(3): p. 222-231. 22. Azechi, H., et al., Disruption of the p16/Cyclin D1/Retinoblastoma Protein Pathway in the Majority of Human Hepatocellular Carcinomas. Oncology, 2001. 60(4). 23. Pimienta, G. and J. Pascual, Canonical and Alternative MAPK Signaling. Cell Cycle, 2007. 6(21): p. 2628-2632. 24. Herbst, A. and K. FT, Wnt signaling as a therapeutic target for cancer. Methods in Molecular Biology, 2007. 361: p. 63-91. 25. Monga, S.P.S., et al., β-catenin antisense studies in embryonic liver cultures: Role in proliferation, apoptosis, and lineage specification. Gastroenterology, 2003. 124(1): p. 202-216. 26. Micsenyi, A., et al., β-Catenin is temporally regulated during normal liver development. Gastroenterology, 2004. 126(4): p. 1134-1146. 27. Devereux, T.R., et al., CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1+. Molecular Carcinogenesis, 2001. 31(2): p. 68-73. 28. Satoh, S. and Y. Y., Multistep carcinogenesis of HCC. Japanese journal of clinical medicine, 2001. 59(6): p. 40-4. 29. Colnot, S., et al., Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2004. 101(49): p. 17216-17221. 30. Tanaka, S., et al., Angiogenic switch as a molecular target of malignant tumors. Journal of Gastroenterol, 2003. 38(15): p. 93-7. 31. Budhu, A. and X.W. Wang, The role of cytokines in hepatocellular carcinoma. Journal of Leukocyte Biology, 2006. 80(6): p. 1197-1213. 32. Schiffer, E., et al., Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology, 2005. 41(2): p. 307-314. 33. Ullrich, A. and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity. Cell, 1990. 61(2): p. 203-212. 34. Schlessinger, J., Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000. 103(2): p. 211-225. 35. Hunter, T., The role of tyrosine phosphorylation in cell growth and disease. Harvey lectures, 1998-1999. 94: p. 81-119. 36. Hubbard, S.R., M. Mohammadi, and J. Schlessinger, Autoregulatory Mechanisms in Protein-tyrosine Kinases. Journal of Biological Chemistry, 1998. 273(20): p. 11987-11990. 37. Schlessinger, J., Regulation of cell growth and transformation by the epidermal growth factor receptor. Advances in experimental medicine and biology, 1988. 234: p. 65-73. 38. Lemmon, M. and J. Schlessinger, Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in biochemical sciences, 1994. 19(11): p. 459-63. 39. Van-Obberghen, E., Signalling through the insulin receptor and the insulin-like growth factor-I receptor. Diabetologia, 1994. 37(2): p. S125-34. 40. Pawson, T. and J. Schlessingert, SH2 and SH3 domains. Current Biology, 1993. 3(7): p. 434-442. 41. Ullrich, A., et al., Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 1984. 309(596): p. 418-25. 42. Kolibaba, K.S. and B.J. Druker, Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1997. 1333(3): p. F217-F248. 43. Robertson, S.C., J.A. Tynan, and D.J. Donoghue, RTK mutations and human syndromes: when good receptors turn bad. Trends in Genetics, 2000. 16(6): p. 265-271. 44. Kaleko, M., W.J. Rutter, and A.D. Miller, Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol., 1990. 10(2): p. 464-473. 45. Salomon, D.S., et al., Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 1995. 19(3): p. 183-232. 46. Stommel, J.M., et al., Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science, 2007. 318(5848): p. 287-290. 47. Huang, P.H., et al., Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences, 2007. 104(31): p. 12867-12872. 48. Vinochani Pillay, L.A., Alex L Wilding, jacqui f donoghue, Naomi W, The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases. . Neoplasia, 2009. 11(5): p. 448-58. 49. Saxena, N.K., et al., Bidirectional Crosstalk between Leptin and Insulin-like Growth Factor-I Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor. Cancer Research, 2008. 68(23): p. 9712-9722. 50. Yamamoto, N., et al., Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. Journal of Cell Science, 2006. 119(22): p. 4623-4633. 51. Reznik, T.E., et al., Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor. Molecular Cancer Research, 2008. 6(1): p. 139-150. 52. Alexander, M., Schlesinger M, Jantscheff P, Massing U, Bendas G., Reduction in human melanoma cell adhesion receptor activity by lysophosphatidylcholine (LPC) treatment - functional characterization and signal pathway analyses. International journal of clinical pharmacology and therapeutics, 2010. 48(7). 53. Cao, K., et al., Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatology Research, 2009. 39(11): p. 1108-1117. 54. Schoeberl, B., et al., Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis. Sci. Signal., 2009. 2(77): p. ra31-. 55. Chang, T. and E.J. Passaro, Intrahepatic stones: the Taiwan experience. American journal of surgery, 1983. 146(2): p. 241-4. 56. Lai, C. and G. Lemke, An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron, 1991. 6(5): p. 691-704. 57. O'Bryan, J.P., et al., AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol., 1991. 11(10): p. 5016-5031. 58. Janssen, J., et al., A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene, 1991. 6(11): p. 2113-20. 59. Rescigno, J., A. Mansukhani, and C. Basilico, A putative receptor tyrosine kinase with unique structural topology. Oncogene, 1991. 6(10): p. 1909-13. 60. Zhang, Y.-X., et al., AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression. Cancer Research, 2008. 68(6): p. 1905-1915. 61. Craven, R., W. Cance, and E. Liu, The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer Reserch, 1995. 55(18): p. 3969-72. 62. Nemoto, T., et al., Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology, 1997. 65(4): p. 195-203. 63. Ito, T., et al., Expression of the AXL receptor tyrosine kinase in human thyroid carcinoma. Thyroid, 1999. 9(6): p. 563-7. 64. Sun, W.S., et al., Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases, AXL and Sky, in human uterine endometrium and ovarian endometriosis. Molecular Human Reproduction, 2002. 8(6): p. 552-558. 65. Wu, C., et al., Clinical significance of AXL kinase family in gastric cancer. Anticancer research, 2002. 22(2B): p. 1071-8. 66. Chung, B.I., et al., Expression of the Proto-Oncogene AXL in Renal Cell Carcinoma. DNA and Cell Biology, 2003. 22(8): p. 533-540. 67. Shieh, Y., et al., Expression of AXL in lung adenocarcinoma and correlation with tumor progression. 2005, 2005. 7(12): p. 1058-64. 68. Allen, M.P., et al., Growth Arrest-Specific Gene 6 (Gas6)/Adhesion Related Kinase (Ark) Signaling Promotes Gonadotropin-Releasing Hormone Neuronal Survival via Extracellular Signal-Regulated Kinase (ERK) and AKT. Molecular Endocrinology, 1999. 13(2): p. 191-201. 69. Linger, R.M.A., et al., TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer, in Advances in Cancer Research. 2008, Academic Press. p. 35-83. 70. Angelillo-Scherrer, A., et al., Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med, 2001. 7(2): p. 215-221. 71. Shankar, S.L., et al., Gas6/AXL Signaling Activates the Phosphatidylinositol 3-Kinase/AKT1 Survival Pathway to Protect Oligodendrocytes from Tumor Necrosis Factor -Induced Apoptosis. The Journal of Neuroscience, 2006. 26(21): p. 5638-5648. 72. Rothlin, C.V., et al., TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response. Cell, 2007. 131(6): p. 1124-1136. 73. Green, J.L., S.G. Kuntz, and P.W. Sternberg, Ror receptor tyrosine kinases: orphans no more. Trends in Cell Biology, 2008. 18(11): p. 536-544. 74. Masiakowski, P. and R. Carroll, A novel family of cell surface receptors with tyrosine kinase-like domain. The Journal of biological chemistry, 1992. 267(36): p. 26181-90. 75. Fukuda, T., et al., Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proceedings of the National Academy of Sciences, 2008. 105(8): p. 3047-3052. 76. Reddy, U., S. Phatak, and D. Pleasure, Human neural tissues express a truncated ROR1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene, 1996. 13(7): p. 1555-9. 77. Nomi, M., et al., Loss of mROR1 Enhances the Heart and Skeletal Abnormalities in mRor2-Deficient Mice: Redundant and Pleiotropic Functions of mROR1 and mRor2 Receptor Tyrosine Kinases. Mol. Cell. Biol., 2001. 21(24): p. 8329-8335. 78. Baskar, S., et al., Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2008. 14(2): p. 396-404. 79. Shabani, M., et al., Overexpression of orphan receptor tyrosine kinase ROR1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour biology 2007. 28(6): p. 318-26. 80. Forrester, W.C., et al., A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature, 1999. 400(6747): p. 881-885. 81. Hikasa, H., et al., The Xenopus receptor tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. Development, 2002. 129(22): p. 5227-5239. 82. Forrester, W.C., C. Kim, and G. Garriga, The Caenorhabditis elegans Ror RTK CAM-1 Inhibits EGL-20/Wnt Signaling in Cell Migration. Genetics, 2004. 168(4): p. 1951-1962. 83. Oishi, I., et al., Spatio-temporally regulated expression of receptor tyrosine kinases, mROR1, mRor2, during mouse development: implications in development and function of the nervous system. Genes to Cells, 1999. 4(1): p. 41-56. 84. Paganoni, S. and A. Ferreira, Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons. Journal of Neuroscience Research, 2003. 73(4): p. 429-440. 85. Paganoni, S., J. Bernstein, and A. Ferreira, ROR1-Ror2 complexes modulate synapse formation in hippocampal neurons. Neuroscience, 2010. 165(4): p. 1261-1274. 86. Gentile, A., et al., ROR1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis. Cancer Research. 71(8): p. 3132-3141. 87. Johnson, D. and L. Williams, Structural and functional diversity in the FGF receptor multigene family. Advances in cancer research, 1993. 60: p. 1-41. 88. Pantoliano, M., et al., Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry, 1994. 33(34): p. 10229-48. 89. Shi, E., et al., Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol. Cell. Biol., 1993. 13(7): p. 3907-3918. 90. Drucker, C., et al., Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis, 2006. 27(1): p. 152-161. 91. Turner, N., et al., FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Research. 70(5): p. 2085-2094. 92. Francavilla, C., et al., Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. Journal of Cell Science, 2007. 120(24): p. 4388-4394. 93. Wüchner, C., et al., Human fibroblast growth factor receptor 3 gene (FGFR3): genomic sequence and primer set information for gene analysis. Human Genetics, 1997. 100(2): p. 215-219. 94. Eswarakumar, V.P., I. Lax, and J. Schlessinger, Cellular signaling by fibroblast growth factor receptors. Cytokine & growth factor reviews, 2005. 16(2): p. 139-149. 95. L’Hote CG, C.G.M. and M.A. Knowles, Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Experimental Cell Research, 2005. 304(2): p. 417-431. 96. Itoh, N. and D.M. Ornitz, Evolution of the Fgf and Fgfr gene families. Trends in Genetics, 2004. 20(11): p. 563-569. 97. Webster, M.K. and D.J. Donoghue, Enhanced signaling and morphological transformation by a membrane- localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol. Cell. Biol., 1997. 17(10): p. 5739-5747. 98. Passos-Bueno, M.R., et al., Clinical spectrum of fibroblast growth factor receptor mutations. Human Mutation, 1999. 14(2): p. 115-125. 99. Cappellen, D., et al., Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 1999. 23(1): p. 18-20. 100. Kimura, T., et al., Mechanisms of Relaxation Induced by Angiotensin II in Isolated Canine and Human Uterine Arteries. Journal of Cardiovascular Pharmacology, 2001. 37(5): p. 585-595. 101. van Rhijn, B.W.G., et al., FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma. Cancer Research, 2004. 64(6): p. 1911-1914. 102. Jang, J.-H., K.-H. Shin, and J.-G. Park, Mutations in Fibroblast Growth Factor Receptor 2 and Fibroblast Growth Factor Receptor 3 Genes Associated with Human Gastric and Colorectal Cancers. Cancer Research, 2001. 61(9): p. 3541-3543. 103. Fan, S.-T., et al., Hepatectomy for Hepatocellular Carcinoma: The Surgeon's Role in Long-term Survival. Arch Surg, 1999. 134(10): p. 1124-1130. 104. Arii, S. and I. M., Physiological role of sinusoidal endothelial cells and Kupffer cells and their implication in the pathogenesis of liver injury. Journal of hepato-biliary-pancreatic surgery, 2000. 7(1): p. 40-8. 105. Palmer, D.H., S.A. Hussain, and P.J. Johnson, Systemic therapies for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2004. 13(12): p. 1555-1568. 106. Farazi, P.A., et al., Cooperative Interactions of p53 Mutation, Telomere Dysfunction, and Chronic Liver Damage in Hepatocellular Carcinoma Progression. Cancer Res., 2006. 66: p. 4766-4773. 107. Tanaka, S. and S. Arii, Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 2009. 100(1): p. 1-8. 108. Tanaka, S. and T.H. Hirohashi K, Shuto T, Lee SH, Kubo S, Takemura S, Yamamoto T, Uenishi T, Kinoshita H., Incidence and management of bile leakage after hepatic resection for malignant hepatic tumors. Journal of the American College of Surgeons, 2002. 195(4): p. 484-9. 109. Normanno, N., et al., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006. 366(1): p. 2-16. 110. Yamaguchi, R., et al., Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 1998. 28(1): p. 68-77. 111. Scharf, J. and T. Braulke, The role of the IGF axis in hepatocarcinogenesis. Hormone and metabolic research. Supplement series, 2003. 35(11-12): p. 685-93. 112. Louafi, S., et al., Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Cancer, 2007. 109(7): p. 1384-1390. 113. Alexia, C., et al., Pleiotropic Effects of PI-3 Kinase/AKT Signaling in Human Hepatoma Cell Proliferation and Drug-Induced Apoptosis. Annals of the New York Academy of Sciences, 2006. 1090(1): p. 1-17. 114. Saxena, N.K., et al., Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells. Cancer Research, 2007. 67(6): p. 2497-2507. 115. Villanueva, A., et al., Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008. 135(6): p. 1972-1983.e11. 116. Zwick, E., B. J, and U. A, Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-related cancer, 2001. 8(3): p. 161-73. 117. Vultur, A., et al., SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Molecular Cancer Therapeutics, 2008. 7(5): p. 1185-1194. 118. Jallal, H., et al., A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo. Cancer Research, 2007. 67(4): p. 1580-1588. 119. Holland, S.J., et al., R428, a Selective Small Molecule Inhibitor of AXL Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer. Cancer Research. 70(4): p. 1544-1554. 120. Bie, P., S. and S. Wamberg, Normotensive sodium loading in conscious dogs: regulation of renin secretion during 帣-receptor blockade. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 2009. 296(2): p. R428-R435. 121. Liu, L., et al., Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL. Cancer Research, 2009. 69(17): p. 6871-6878. 122. Li, Y., et al., AXL as a potential therapeutic target in cancer: role of AXL in tumor growth, metastasis and angiogenesis. Oncogene, 2009. 28(39): p. 3442-3455. 123. Xu, M.Z., et al., AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene, 2011. 30(10): p. 1229-1240. 124. Trudel, S., et al., The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 2006. 107(10): p. 4039-4046. 125. Qing, J., et al., Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. The Journal of Clinical Investigation, 2009. 119(5): p. 1216-1229. 126. Shenxian Qian, George Somlo, and a.Y.Y. Bingsen Zhou, Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3. Therapeutics and clinical risk management, 2005. 1(3): p. 231–241. 127. Zhu, L., et al., Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Molecular Cancer Therapeutics, 2005. 4(5): p. 787-798. 128. Trudel, S., et al., CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 2005. 105(7): p. 2941-2948. 129. Chen, J., et al., FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene, 2005. 24(56): p. 8259-8267. 130. Bernard-Pierrot, I., et al., Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 2006. 27(4): p. 740-747. 131. Shao, R.-X., et al., Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology, 2005. 128(1): p. 86-95. 132. Thorgeirsson, S.S. and J.W. Grisham, Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet., 2002. 31: p. 339-346. 133. Marotta, F. and C.A. Vangieri B, Gattoni A., The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. La Clinica terapeutica. 155(5): p. 187-99. 134. Sun, S., et al., Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver International, 2007. 27(8): p. 1021-1038. 135. Wong, C.-M. and I.O.L. Ng, Molecular pathogenesis of hepatocellular carcinoma. Liver International, 2008. 28(2): p. 160-174. 136. Zhu, A.X., Successful targeted therapies for hepatocellular carcinoma: are we really getting there? Expert Review of Anticancer Therapy, 2008. 8(4): p. 499-505. 137. Karapetis, C.S., et al., K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 2008. 359(17): p. 1757-1765. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38540 | - |
dc.description.abstract | 肝細胞癌(Hepatocellular carcinoma, HCC)在台灣位居第二的癌症死因,並於全球為第六大癌症。肝細胞癌通常難以及早發現,因為往往於中期才可被發現。由於不同肝癌患者症狀及基因表現差異極大,且致病因素相當廣泛,肝癌被認為是一個極複雜的疾病。肝細胞癌的分子機制,特別是早期,目前仍未十分清楚。分析不同的腫瘤中有時會發現牽涉到不同的傳導途徑。受器酪胺酸激脢(Receptor Tyrosine Kinase, RTK)在胚胎發育及許多生理機制上皆參與傳遞,在人類癌症致病過程中扮演非常關鍵性的角色,此外,因為受器酪胺酸激脢成為可被藥物抑制,受器酪胺酸激脢也是大部份標靶治療的標的。
我們利用人類的受器酪胺酸激脢陣列尋找在肝細胞癌中主要被活化的受器酪胺酸激脢,我們發現EGFR, IGF1R是最常被活化的受器酪胺酸激脢。我們選擇Ror1, AXL, and FGFR3作為研究的目標。這些基因被敲減(knockdown)時會抑制下游訊息傳遞,被磷酸化的AKT幾乎消失,而當AXL and FGFR3被敲減時,被磷酸化的ERK也有些微減少。雖然細胞增生的能力並無明顯的改變,但生成腫瘤的能力卻下降。我們以bosutinib抑制AXL時,發現細胞移動能力下降。總結來說,抑制此三個受器酪胺酸激脢中其中任一個,可能影響肝細胞癌細胞的生長或移動。 ROR1, AXL,及FGFR3可能可以提供肝細胞癌標靶治療的新標的,因為肝細胞癌複雜的致病機制,我們需要對其訊息傳遞途徑更多瞭解,以發展更有系統的治療方式。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the second most common cause of cancer mortality in Taiwan and the sixth most common malignancy worldwide. The risks are the highest in South-East Asia and sub-Saharan Africa. HCC typically has poor prognosis because it is often diagnosed at an advanced stage. Because of the heterogeneous phenotypic and genetic traits of patients and a wide range of risk factors, HCC is considered as a complex disease. The molecular mechanisms of HCC, particularly in the early stage, are still poorly understood. Analysis of different tumors revealed several core pathways are frequently altered in certain types of cancer. Receptor tyrosine kinases (RTK) are critically involved in the progression of human cancer. Besides, RTKs are the targets of most molecularly targeted therapy. Therefore, RTKs offer unique opportunities for pharmacological intervention.
Here we used the human phospho-RTK Array to define the compendium of activated RTKs in HCC. We found several RTKs constitutively expressed in HCC cell lines. EGFR and IGF1R are the most commonly activated RTKa. We choose ROR1, AXL, and FGFR3 as the potential targets to study. Knockdown of these genes was accompanied by inhibition of downstream signaling events. In western blotting, pAKT were almost abolished when these three genes were knocked down individually, and knockdown of AXL and FGFR3 also slightly reduced phosphorylation of ERK. Colony formation ability was measured by soft agar assay. The colony formation ability decreased in all the knockdown cell lines. MTT assay was used to detect the proliferation ability and shows that knockdown cells do not have significantly reduced proliferation ability. Targeting AXL by bosutinib inhibits HCC cells migration. In conclusion, inactivation of any single one of these three RTKs may affect HCC cell growth or migration. Our study of ROR1, AXL, and FGFR3 might offer new opportunities for therapeutic intervention. Since HCC has complex network of signaling pathway, it is important for us to further identify the downstream signaling pathways to develop the more effective systemic treatment option. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:36:43Z (GMT). No. of bitstreams: 1 ntu-100-R94444004-1.pdf: 3889302 bytes, checksum: 362d1ca1d8874c120e3a8b4b11d44ddb (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Contents
口試委員審定書..........................................................................................I 誌 謝......................................................................................................... II 中文摘要…………………………………………………………………III Abstract………………………………………………………………..…IV Content……………………………………………………………...…....VI 1. Introduction 1.1 Hepatocellular carcinoma (HCC)…………………………………………… 1 1.2 Risk factors…………………………….…………………………………….... 1 1.3 Symptoms……………………………………………………………………….2 1.4 Molecular mechanisms of HCC……………………………………………….3 1.5 Receptor Tyrosine kinase (RTK)………………………………………………5 1.6 RTK coactivation……………………………………………………………….7 2. Materials and Methods 2.1 Cell culture………………………………………………………………………9 2.2 RTK array……………………………………………………………………….9 2.3 RNA interference………………………………………………………………10 2.4 RNA isolation…………………………………………………………………..11 2.5 RT-PCR…………………………………………………………………………11 2.6 Western blotting………………………………………………………………..12 2.7 Soft agar assay……………………………………….…………………………13 2.8 Cell proliferation assay (MTT assay)…………………………………………13 2.9 Migration Assay………………………………………………………………..14 3. Result 3.1 Several RTKs are activated in most HCC cell lines………………………….15 3.2 RTK genes knockdown in HCC cell lines no significantly reduction in proliferation………………….……………………………...……16 3.3 Knockdown of ROR1, AXL, FGFR3 in HCC cell lines reduces anchorage-independent growth………………………………………17 3.4 Knockdown of RTK genes ROR1, AXL, FGFR3 in HCC cell lines reduce tumorigenetic pathway signaling……………………..17 3.5 Targeting AXL by Bosutinib Inhibit the HCC Cell Migration but not proliferation……………………………………………………………18 4. Discussion 4.1 Multiple receptor tyrosine kinases are expressed in HCC…………………...19 4.2 AXL, ROR1, FGFR3 may involve the tumorigenesis pathway……………...20 4.3 Target therapy in hepatocellularcCarcinoma………………………………...24 4.4 Conclusions……………………………………………………………………...30 5. Reference………………………………………………………………33 6. Figure and Table………………………………………………………43 7. Appendix……………………………………………………………….57 | |
dc.language.iso | en | |
dc.title | 肝細胞癌中活化之受器酪胺酸激脢之尋找及分析 | zh_TW |
dc.title | Identification and Analysis of Activated Receptor Tyrosine Kinase in Hepatocellular Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 譚賢明,周涵怡,張亨? | |
dc.subject.keyword | 肝細胞癌,受器酪胺酸激脢, | zh_TW |
dc.subject.keyword | Hepatocellular carcinoma,Receptor tyrosine kinase, | en |
dc.relation.page | 84 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 3.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。